glp-1 prices drop Patients Face New Barriers for Drugs McKee's proposed FY2027 budget drops

The potential role of GLP-1 agonists in treating alcohol use disorder (AUD) has emerged from both animal studies and early-phase human trials, though it is important to emphasise that there is no official licence for these medications in AUD treatment in the UK or elsewhere

For many, non-surgical treatments offer a less invasive alternative, but when dramatic change is needed, surgery remains the gold standard

Reconstituted proteins degrade rapidly at room temperature

Approval of the drug would be a win for Lilly as it tries to maintain dominance over the GLP-1 market, where it has already overtaken rival company Novo Nordisk, manufacturer of Ozempic and Wegovy

This is an excellent medication

As GLP-1 therapies expand beyond diabetes and obesity, understanding their anti-inflammatory mechanisms may unlock new therapeutic uses